Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer [5]

Journal of the National Cancer Institute

Volumn 93, Issue 3, 2001, Pages 240-241

  Ménard, Sylvie ^a   Camerini, Tiziana ^a   Mariani, Luigi ^a   Tomasic, Gorana ^a   Pilotti, Silvana ^a   Costa, Alberto ^a   De Palo, Giuseppe ^a   Veronesi, Umberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FENRETINIDE; PROGESTERONE RECEPTOR; RETINOID; SOMATOMEDIN C; STEROID HORMONEENDOGENOUS COMPOUND; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; EARLY CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER;

EID: 0035819525     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.3.240     Document Type: Letter

References (6)

1. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
2. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide
3. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors
4. Distribution of fenretinide in the mammary gland of breast cancer patients
5. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients
6. Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis